Biopharma Insights | BiopharmaTrend

The Bigger Point Beyond Insilico's Aging Research Milestone

This week Insilico Medicine, an AI-driven drug discovery company, reported an unusual experiment. Arguably for the first time, aging biomarkers were written prospectively into a controlled trial run for a …

Continue ›››

The Measurement Challenge in Longevity: Can Aging Biomarkers and Clocks Close the Gap?

An article published in Nature Biotechnology on 7 September 2026 by Alex Zhavoronkov’s team at Insilico Medicine and collaborators marks an important step forward for the field of drugs targeting …

Continue ›››

What Do the New AI Model Releases by Anthropic and OpenAI Change for Life Sciences?

Last week, Anthropic and OpenAI released new frontier models, specifically, Anthropic shipped Claude Fable 5.1 and a restricted variant called Mythos 5.1, while OpenAI shipped GPT-6 Astra. OpenAI president, Greg …

Continue ›››

Into the Dark: Finding Novel Drug Targets Within the Depths of Our Proteome

Drug discovery has never had a richer therapeutic toolbox. Antibody-drug conjugates, antisense oligonucleotides, CRISPR therapeutics, RNA medicines, CAR-T cells, PROTACs, and molecular glues have transformed how medicine can manipulate biology. …

Continue ›››

Beyond the Code: How DNA Nanotechnology is Moving from Molecular Origami to Programmable Biotech Platforms

Biotech treats DNA primarily as a coding material that provides information about disease phenotypes and can serve as a drug target and modality. But beyond the code, DNA is also …

Continue ›››

Seven HealthTech Trends In Europe To Watch

I spent last week in Amsterdam, attending HLTH Europe 2026, arguably Europe's flagship healthcare innovation event, hosting more than 5,000 attendees. It is my second HLTH experience, and two additions …

Continue ›››

Self-Care Is Not a Product, It’s Critical Infrastructure: Why We Must Work Together to Make Health Systems Resilient.

The System Is Buckling; Self-Care Is the Solution. Global health systems are buckling under immense pressure. When I attended the World Health Assembly in May, Dr. Wael Ali, board member …

Continue ›››

Ginkgo Datapoints, Tangible Scientific, and Inductive Bio Launch ADME-One, a Packaged ADME Service for Early Discovery

Ginkgo Bioworks' (NYSE: DNA) Datapoints arm, Tangible Scientific, and Inductive Bio today launched ADME-One, a single-SKU service that combines a Tier 1 ADME panel, AI-driven human pharmacokinetic projection, and compound …

Continue ›››

AI Won't Replace Clinical Programmers. It Will Split Them Into Two Groups.

In a recent large-scale code modernization initiative, a team used generative AI to convert a clinical data standards library from one programming language to another. Nearly 80% of the templates …

Continue ›››

Unlocking the Full Potential of Precision Medicine: Why Companion Diagnostics Must Start at Discovery

Precision medicine has transformed the way we treat cancer, making it possible to match therapies to the molecular profile of each patient and revolutionize treatment approaches, leading to better outcomes. …

Continue ›››

From Electronic Noses to Agentic Drug Design: What Cancer AI Looks Like Now

Cancer AI has moved into some unusual territory. In one recent example, researchers at Linköping University reported that a 32-sensor electronic nose could distinguish ovarian cancer in blood plasma in …

Continue ›››

Tamarind Bio Raises $13.6M to Run 200+ AI and Simulation Models in a No-Code Platform for Bench Scientists

Tamarind Bio has secured $13.6 million in Series A financing led by Dimension Capital with participation from Y Combinator to expand its platform for coordinating and deploying AI models in …

Continue ›››